Bandicoot_Inv
2 days ago
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
βAt Absci, weβre constantly pushing the boundaries of innovation to bring better biologics to patients faster,β said Sean McClain, Founder and CEO of Absci. βBy combining Absciβs AI de novo design expertise with Owkinβs world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.β
Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkinβs predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absciβs generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.
βAt Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,β said Thomas Clozel, MD, CEO and Co-Founder of Owkin. βThis partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkinβs AI agents that can identify and experimentally validate novel therapeutic targets with Absciβs pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.β
This collaboration builds on Absciβs growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics
Bandicoot_Inv
2 days ago
ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.
Monksdream
3 months ago
C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (Weβre not saying that to make your Claude-drafted emails look bad, we promise.)
Absciβs CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies fasterβand cheaperβthan ever before.
Absci uses E. coliβyes, the same bacteria that can give you some nasty infectionsβto manufacture antibodies that can be used in a variety of therapies. Using a process called βhigh throughput screening,β it then tests the antibodies, and it patents therapies containing the most promising ones.
Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became βthe nucleusβ that it built a proprietary AI around, Jonasson said.
ANTADOG
6 months ago
recoverin' above 50ma, co is busy, 2025 should be great, meanwhile, we have 4,50 and 5,00 as nxt resistances, patience, ANT